Trials / Completed
CompletedNCT03510104
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Meryx, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Neoplasms
- Neoplasm Metastasis
- Neoplastic Processes
- Pathologic Processes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRX-2843 | MRX-2843 capsules |
Timeline
- Start date
- 2018-05-22
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2018-04-27
- Last updated
- 2026-01-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03510104. Inclusion in this directory is not an endorsement.